Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.62 |
| ▸ | CPB1 | P15086 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | CTSK | P43235 | 3/20 | 0.60 |
| ▸ | CTSS | P25774 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24515807 | 1.00 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL10007480 | 0.97 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL6200837 | 0.97 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL22204568 | 0.97 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL6200834 | 0.97 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL6082958 | 0.97 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL5345577 | 0.97 | CASP3 (0.62) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL25391512 | 0.96 | CASP3 (0.61) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL3063260 | 0.91 | CPB1 (0.72) | CASP3CPB1ALDH1A1GAACTSB | |
| SCHEMBL10148184 | 0.91 | CPB1 (0.72) | CASP3CPB1ALDH1A1GAACTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | CASP3 1623/4885CPB1 1589/4885ALDH1A1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.